Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Vanda Pharmaceuticals Inc (NASDAQ: VNDA) was $7.34 for the day, down -14.05% from the previous closing price of $8.54. In other words, the price has decreased by -$14.05 from its previous closing price. On the day, 3.66 million shares were traded. VNDA stock price reached its highest trading level at $7.938 during the session, while it also had its lowest trading level at $7.31.
Ratios:
Our analysis of VNDA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.10 and its Current Ratio is at 3.12. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, B. Riley Securities on November 05, 2025, initiated with a Buy rating and assigned the stock a target price of $11.
On October 31, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $18.
On July 11, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $11.Cantor Fitzgerald initiated its Overweight rating on July 11, 2024, with a $11 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 07 ’25 when Polymeropoulos Mihael Hristos bought 10,000 shares for $4.15 per share. The transaction valued at 41,500 led to the insider holds 2,335,731 shares of the business.
Mitchell Stephen Ray sold 7,000 shares of VNDA for $32,130 on Jun 13 ’25. The Director now owns 97,082 shares after completing the transaction at $4.59 per share. On Jun 13 ’25, another insider, Mitchell Stephen Ray, who serves as the Director of the company, bought 7,000 shares for $4.59 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VNDA now has a Market Capitalization of 433769280 and an Enterprise Value of 150932272. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.05 while its Price-to-Book (P/B) ratio in mrq is 0.93. Its current Enterprise Value per Revenue stands at 0.712 whereas that against EBITDA is -1.335.
Stock Price History:
The Beta on a monthly basis for VNDA is 0.63, which has changed by 0.8565217 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, VNDA has reached a high of $9.60, while it has fallen to a 52-week low of $3.81. The 50-Day Moving Average of the stock is 26.20%, while the 200-Day Moving Average is calculated to be 49.30%.
Shares Statistics:
VNDA traded an average of 1.56M shares per day over the past three months and 4462580 shares per day over the past ten days. A total of 59.10M shares are outstanding, with a floating share count of 55.08M. Insiders hold about 6.79% of the company’s shares, while institutions hold 77.31% stake in the company. Shares short for VNDA as of 1765756800 were 4892408 with a Short Ratio of 3.14, compared to 1763078400 on 3882165. Therefore, it implies a Short% of Shares Outstanding of 4892408 and a Short% of Float of 8.59.
Earnings Estimates
The market rating of Vanda Pharmaceuticals Inc (VNDA) is currently shaped by the ongoing analysis conducted by 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.24 and low estimates of -$0.56.
Analysts are recommending an EPS of between -$1.77 and -$3.54 for the fiscal current year, implying an average EPS of -$2.67. EPS for the following year is -$1.45, with 4.0 analysts recommending between -$0.36 and -$2.42.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 4 analysts. It ranges from a high estimate of $62.5M to a low estimate of $56.9M. As of . The current estimate, Vanda Pharmaceuticals Inc’s year-ago sales were $53.19MFor the next quarter, 4 analysts are estimating revenue of $61.8M. There is a high estimate of $64M for the next quarter, whereas the lowest estimate is $57.4M.
A total of 4 analysts have provided revenue estimates for VNDA’s current fiscal year. The highest revenue estimate was $221.4M, while the lowest revenue estimate was $215.8M, resulting in an average revenue estimate of $218.17M. In the same quarter a year ago, actual revenue was $198.77MBased on 4 analysts’ estimates, the company’s revenue will be $271.27M in the next fiscal year. The high estimate is $298M and the low estimate is $236.4M.
